OncoMatch

OncoMatch/Clinical Trials/NCT05254171

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Is NCT05254171 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including SBP-101 and Nab-paclitaxel for pancreatic cancer metastatic.

Phase 2/3RecruitingPanbela Therapeutics, Inc.NCT05254171Data as of May 2026

Treatment: SBP-101 · Nab-paclitaxel · Gemcitabine — The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Biomarker criteria

Excluded: BRCA1 mutation

Excluded: BRCA2 mutation

Disease stage

Required: Stage IV

Metastatic disease required

metastatic pancreatic ductal adenocarcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Blood counts

Adequate bone marrow function as outlined in protocol

Kidney function

Adequate renal function as outlined in protocol

Liver function

Adequate hepatic function as outlined in protocol

Cardiac function

QTc interval ≤ 470 ms (for women) and ≤ 450 ms (for men) on the ECG at baseline calculated by either the Fridericia or Framingham formula

Adequate bone marrow, hepatic and renal function as outlined in protocol. QTc interval ≤ 470 ms (for women) and ≤ 450 ms (for men) on the ECG at baseline calculated by either the Fridericia or Framingham formula.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Genesis Cancer and Blood Institute (SCRI) · Hot Springs, Arkansas
  • Providence Medical Foundation · Fullerton, California
  • Yale Cancer Center · New Haven, Connecticut
  • MedStar Georgetown University Hospital · Washington D.C., District of Columbia
  • Henry Ford Health System · Detroit, Michigan

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify